A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Watch (Dutch & English): Just five companies...
Media - published on 20 Nov 2018

Watch (Dutch & English): Just five companies developing the bulk of urgently needed new medicines

Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation talks to NOS News about one of the key findings of the 2018 Access to Medicine Index: just five pharmaceutical companies are developing the bulk of urgently needed new medicines for the poor.

“It’s a problem when its concentrated on these five because if any one of them changes their strategy, it can have a really catastrophic effect on our ability to bring innovation to the table and our ability to progress on access to medicine.”  - Jayasree K. Iyer.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |